艾瑞昔布片治疗退行性膝关节炎的临床疗效观察
|
摘要
目的观察艾瑞昔布片治疗退行性膝关节炎的临床疗效。方法 108例退行性膝关节炎患者接受口服艾瑞昔布片治疗8周,通过视觉模拟评分法(VAS)和Lysholm膝关节评分,分析治疗前,治疗后第2、4、6、8周的疼痛程度和膝关节功能。结果随着治疗时间的延长,患者疼痛VAS评分逐渐降低,膝关节功能改善Lysholm膝关节评分逐渐升高,差异均有统计学意义(P<0.05)。结论艾瑞昔布片治疗退行性膝关节炎疗效确切,值得临床推广。
Objective To discuss the clinical efficacy and safety of imrecoxib tablets for curing the retrogressive knee arthritis.Methods 108 patients with retrogressive knee arthritis receive oral imrecoxib tablets treatment for 8 weeks.By the visual analogue scale( VAS) and the Lysholm knee grade,analysis level of pain and knee joint function before treatment and after treatment for 2,4,6,8 weeks.Results With the extension of treatment time,the pain VAS score of patients gradually reduce,knee joint function improve,the Lysholm knee grade gradually increase.the differences were statistically significant( P <0.05).Conclusion The clinical efficacy of Imrecoxib Tablets for curing the retrogressive knee arthritis is definite,is worthy of clinical promotion.
Objective To discuss the clinical efficacy and safety of imrecoxib tablets for curing the retrogressive knee arthritis.Methods 108 patients with retrogressive knee arthritis receive oral imrecoxib tablets treatment for 8 weeks.By the visual analogue scale( VAS) and the Lysholm knee grade,analysis level of pain and knee joint function before treatment and after treatment for 2,4,6,8 weeks.Results With the extension of treatment time,the pain VAS score of patients gradually reduce,knee joint function improve,the Lysholm knee grade gradually increase.the differences were statistically significant( P <0.05).Conclusion The clinical efficacy of Imrecoxib Tablets for curing the retrogressive knee arthritis is definite,is worthy of clinical promotion.
引文
[1]郭宗儒.国家1类新药艾瑞昔布的研制[J].2012,21(3):223-230.
[2]Orthopaedic S,Anupam H,Bhagat SC.Chondroprotection using naturally occurring mineral supplementation formula in degener-ative osteoarthritis of the Knees[J].Journal of Stem Cells,2014,9(1):65.
[3]孙小琴,徐兰凤.近10年骨性膝关节炎的治疗方法综述[J].针灸临床杂志,2009,25(2):46-48.
[4]徐东,张奉春,古洁若,等.艾瑞昔布治疗膝骨关节炎的Ⅲ期多中心随机双盲临床试验[J].中华临床免疫和变态反应杂志,2014,8(3):205-210.
[5]Zang W,Moskowitz RW,Nuki G,et al.国际骨关节炎研究学会髋与膝骨关节炎治疗指南第二部分基于循证和专家共识之治疗指南[J].曹月龙,高宁阳,庞坚,等,译.国际骨科学杂志,2009,30(4):208-217.
[6]刘康宝.中老年膝骨关节炎发病的先关因素分析[J].世界最新医学信息文摘,2015,15(31):6-7.
[7]黄建林,古洁若,潘云峰,等.艾瑞昔布片治疗膝骨关节炎的Ⅱ期多中心随机双盲临床试验[J].中国药学杂志,2011,46(22):1740-1745.
[8]徐鹏慧.选择性COX-2抑制剂对中轴脊柱关节炎的疗效及血清DKK-1水平的影响[D].郑州:郑州大学,2012.
[9]李彬.中药内服外敷治疗退行性膝关节炎的临床观察[J].中医药导报,2010,16(11):59-60.
[10]柯铭锋,林泉,林久灶.口服COX-2抑制剂对超前镇痛的疗效及安全性简析[J].国伤残医学,2009,17(6):63-64.
[2]Orthopaedic S,Anupam H,Bhagat SC.Chondroprotection using naturally occurring mineral supplementation formula in degener-ative osteoarthritis of the Knees[J].Journal of Stem Cells,2014,9(1):65.
[3]孙小琴,徐兰凤.近10年骨性膝关节炎的治疗方法综述[J].针灸临床杂志,2009,25(2):46-48.
[4]徐东,张奉春,古洁若,等.艾瑞昔布治疗膝骨关节炎的Ⅲ期多中心随机双盲临床试验[J].中华临床免疫和变态反应杂志,2014,8(3):205-210.
[5]Zang W,Moskowitz RW,Nuki G,et al.国际骨关节炎研究学会髋与膝骨关节炎治疗指南第二部分基于循证和专家共识之治疗指南[J].曹月龙,高宁阳,庞坚,等,译.国际骨科学杂志,2009,30(4):208-217.
[6]刘康宝.中老年膝骨关节炎发病的先关因素分析[J].世界最新医学信息文摘,2015,15(31):6-7.
[7]黄建林,古洁若,潘云峰,等.艾瑞昔布片治疗膝骨关节炎的Ⅱ期多中心随机双盲临床试验[J].中国药学杂志,2011,46(22):1740-1745.
[8]徐鹏慧.选择性COX-2抑制剂对中轴脊柱关节炎的疗效及血清DKK-1水平的影响[D].郑州:郑州大学,2012.
[9]李彬.中药内服外敷治疗退行性膝关节炎的临床观察[J].中医药导报,2010,16(11):59-60.
[10]柯铭锋,林泉,林久灶.口服COX-2抑制剂对超前镇痛的疗效及安全性简析[J].国伤残医学,2009,17(6):63-64.